Myeloproliferative Disorders (MPD)
Leukemia Insights - Summer 2008
The development of novel therapies for patients with MPD has been historically hampered by limited understanding of the abnormal processes and molecular causes of these diseases. The discovery of JAK2 mutation in most MPD patients is a first step in this direction. Agents potentially able to interfere with identified abnormalities in MPD are becoming available.
Available programs are listed below:
a. Pegylated interferon (Pegasys) for ET and PV: protocol DM03-0109
b. Obatoclax (pan bcl-2 inhibitor) in MF: protocol 2006-0411
c. Pomalidomide (CC-4047): protocol 2006-0817
d. CEP-701 in MF: protocol 2007-0070
e. INCB018424 in MF: protocol 2007-0169
f. XL019 in MF: protocol 2007-0373
g. TG101348 in MF: protocol 2007-0837
For additional information about the therapies for MPD at M. D. Anderson Cancer Center, visit the MPD website or contact Srdan Verstovsek, MD, PhD, MPD Program Leader, at (713) 745-3429; e-mail firstname.lastname@example.org.